By Senator Harrell

	25-01462-21 20211392
1	A bill to be entitled
2	An act relating to health insurance coverage for
3	cancer treatment; amending s. 627.4239, F.S.; defining
4	the terms "associated condition" and "health care
5	provider"; prohibiting health maintenance
6	organizations from excluding coverage for certain
7	cancer treatment drugs; prohibiting health insurers
8	and health maintenance organizations from requiring,
9	before providing prescription drug coverage for the
10	treatment of stage 4 metastatic cancer and associated
11	conditions, that treatment has failed with a different
12	drug; providing applicability; prohibiting insurers
13	and health maintenance organizations from excluding
14	coverage for certain drugs on certain grounds;
15	prohibiting insurers and health maintenance
16	organizations from requiring that certain cancer
17	treatment drugs be sent to certain entities for home
18	infusion unless a certain condition is met; revising
19	construction; providing an effective date.
20	
21	Be It Enacted by the Legislature of the State of Florida:
22	
23	Section 1. Section 627.4239, Florida Statutes, is amended
24	to read:
25	627.4239 Coverage for use of drugs in treatment of cancer
26	(1) DEFINITIONS.—As used in this section, the term:
27	(a) "Associated condition" means a symptom or side effect
28	that:
29	1. Is associated with a particular cancer at a particular

Page 1 of 4

	25-01462-21 20211392
30	stage or with the treatment of that cancer; and
31	2. In the judgment of a health care provider, will further
32	jeopardize the health of a patient if left untreated. As used in
33	this subparagraph, the term "health care provider" means a
34	physician licensed under chapter 458, chapter 459, or chapter
35	461, a physician assistant licensed under chapter 458 or chapter
36	459, an advanced practice registered nurse licensed under
37	chapter 464, or a dentist licensed under chapter 466.
38	(b) "Medical literature" means scientific studies published
39	in a United States peer-reviewed national professional journal.
40	<u>(c)</u> (b) "Standard reference compendium" means authoritative
41	compendia identified by the Secretary of the United States
42	Department of Health and Human Services and recognized by the
43	federal Centers for Medicare and Medicaid Services.
44	(2) COVERAGE FOR TREATMENT OF CANCER
45	(a) An insurer <u>or a health maintenance organization</u> may not
46	exclude coverage in any individual or group <u>health</u> insurance
47	policy or health maintenance contract issued, amended,
48	delivered, or renewed in this state which covers the treatment
49	of cancer for any drug prescribed for the treatment of cancer on
50	the ground that the drug is not approved by the United States
51	Food and Drug Administration for a particular indication, if
52	that drug is recognized for treatment of that indication in a
53	standard reference compendium or recommended in the medical
54	literature.
55	(b) Coverage for a drug required by this section also
56	includes the medically necessary services associated with the
57	administration of the drug.
58	(3) COVERAGE FOR TREATMENT OF STAGE 4 METASTATIC CANCER AND

Page 2 of 4

	25-01462-21 20211392
59	ASSOCIATED CONDITIONS
60	(a) An insurer or a health maintenance organization may not
61	require in any individual or group health insurance policy or
62	health maintenance contract issued, amended, delivered, or
63	renewed in this state which covers the treatment of stage 4
64	metastatic cancer and its associated conditions that, before a
65	drug prescribed for the treatment is covered, the insured or
66	subscriber fail or have previously failed to respond
67	successfully to a different drug.
68	(b) Paragraph (a) applies to a drug that is recognized for
69	the treatment of such stage 4 metastatic cancer or its
70	associated conditions, as applicable, in a standard reference
71	compendium or that is recommended in the medical literature. The
72	insurer or health maintenance organization may not exclude
73	coverage for such drug on the ground that the drug is not
74	approved by the United States Food and Drug Administration for
75	such stage 4 metastatic cancer or its associated conditions, as
76	applicable.
77	(4) COVERAGE FOR SERVICES ASSOCIATED WITH DRUG
78	ADMINISTRATIONCoverage for a drug required by this section
79	also includes the medically necessary services associated with
80	the administration of the drug.
81	(5) PROHIBITION ON MANDATORY HOME INFUSION.—An insurer or a
82	health maintenance organization may not require that a cancer
83	medication be administered using home infusion, and may not
84	require that such medication be sent directly to a third party
85	or to the patient for home infusion unless the patient's
86	treating oncologist determines that home infusion of the cancer
87	medication will not jeopardize the health of the patient.

Page 3 of 4

I	25-01462-21 20211392
88	(6)-(3) APPLICABILITY AND SCOPE.—This section may not be
89	construed to:
90	(a) Alter any other law with regard to provisions limiting
91	coverage for drugs that are not approved by the United States
92	Food and Drug Administration, except for drugs for the treatment
93	of stage 4 metastatic cancer or its associated conditions.
94	(b) Require coverage for any drug, except for a drug for
95	the treatment of stage 4 metastatic cancer or its associated
96	conditions, if the United States Food and Drug Administration
97	has determined that the use of the drug is contraindicated.
98	(c) Require coverage for a drug that is not otherwise
99	approved for any indication by the United States Food and Drug
100	Administration, except for a drug for the treatment of stage 4
101	metastatic cancer or its associated conditions.
102	(d) Affect the determination as to whether particular
103	levels, dosages, or usage of a medication associated with bone
104	marrow transplant procedures are covered under an individual or
105	group health insurance policy or health maintenance organization
106	contract.
107	(e) Apply to specified disease or supplemental policies.
108	<u>(f)</u> (4) Nothing in this section is intended, Expressly or by
109	implication, to create, impair, alter, limit, modify, enlarge,
110	abrogate, prohibit, or withdraw any authority to provide
111	reimbursement for drugs used in the treatment of any other
112	disease or condition.
113	Section 2. This act shall take effect January 1, 2022.

Page 4 of 4